Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $11.82M (cash outflow) rose 5.5% year over year, ahead of the -21.6% change in trailing-twelve-month net income. Sequentially, it rose 53.2% from the prior quarter. Over 3 fiscal years it compounded at +11.9% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$30.67M (-22.5%) for the fiscal year ending Dec 2026, a step up from the -23.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.82M+53.2% QoQ
- Last fiscal yearDec 2025
- -$39.57M-23.8% YoY
- LTMMar 2026
- -$40.19M-21.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.5% | -2.1% | -7.5 pp |
| 1 year | -23.8% | -22.5% | +1.3 pp |
| 3-year CAGR | +11.9% | +8.5% | -3.5 pp |
| 5-year CAGR | +2.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (39.57M) USD
- Year-over-year change
- +23.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.57M) | +23.8% |
| FY2024 | 2024-12-31 | (51.9M) | -47.5% |
| FY2023 | 2023-12-31 | (35.2M) | -24.8% |
| FY2022 | 2022-12-31 | (28.21M) | -6.8% |
| FY2021 | 2021-12-31 | (26.4M) | — |
Net Income vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -21.6% is the 7th highest of 9, against a peer median of -9.3%.
- Over three fiscal years its annual growth of +11.9% compares with a peer median of +3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $68.36M USD | +31.7% | +2.6% | 3832.0% | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| LTM Mar 2026 | $44.76M USD | -8.4% | +5.8% | 8526.1% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| LTM Mar 2026 | $31.7M USD | -25.4% | -22.3% | 1000.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M USD | -14.9% | +3.3% | — |
| Peer median (excluding ELTX) | — | -9.3% | +3.3% | 3832.0% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.4M) | (28.21M) | (35.2M) | (51.9M) | (39.57M) |
| Depreciation & Amortization | 251.45K | 1.06M | 1.17M | 1.18M | 1.13M |
| Deferred Income Tax | 52.96K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 617.76K | 579K | 1.18M | 1.45M | 2.7M |
| Change in Working Capital | 872.44K | (150K) | (57K) | 3.96M | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 30.23K | 1.13M | 23K | (3.33M) | (366K) |
| Other Working Capital | 842.21K | (1.28M) | (80K) | 7.29M | (3.08M) |
| Other Non-Cash Items | 667.05K | 4.54M | 209K | 8.24M | 2.24M |
| Operating Cash Flow | (23.94M) | (22.18M) | (32.69M) | (37.07M) | (36.95M) |
| Capital Expenditures | (525.36K) | (654K) | (66K) | (87K) | (16K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 34K | 3K | 0 |
| Investing Cash Flow | (525.36K) | (654K) | (32K) | (84K) | (16K) |
| Debt Repayment | 14.03M | 0 | 10M | 19.73M | 9.87M |
| Common Stock Issued | 101.38K | 82K | 7M | 5.64M | 26.83M |
| Common Stock Repurchased | 0 | 0 | (150K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 314.88K | 82K | 21.76M | 16.96M | 0 |
| Financing Cash Flow | 19.39M | 21.2M | 38.61M | 42.32M | 36.7M |
| Effect of Forex Changes | 3K | 0 | (68K) | 22K | 40K |
| Net Change in Cash | (5.07M) | (1.63M) | 5.89M | 5.19M | (233K) |
| Free Cash Flow | (24.46M) | (22.83M) | (32.76M) | (37.16M) | (36.97M) |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.